The hypothesis being tested in this trial is that promoting adherence to the MedDiet as an adjuvant to standard treatments for MDD can reduce symptoms of depression in patients with MDD and elevated inflammation biomarkers (IL-6 and CRP). This evidence concerns the gene CRP and major depressive disorder.